ENDRA Life Sciences Inc. Common Stock (NDRA)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I start with the business, not the story. ENDRA Life Sciences is a nine-employee diagnostics developer trying to improve clinical ultrasound for fatty liver disease. The technology may be promising, but the filed figures show no revenue in any period listed. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported net income of $159,944 and diluted EPS of $0.06—encouraging, but isolated. In fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$1.3M and diluted EPS -$1.09. For fiscal 2025, the year ended 2025-12-31, net income was -$7.0M and diluted EPS -$8.93; fiscal 2024, the year ended 2024-12-31, was -$11.5M; and fiscal 2023, the year ended 2023-12-31, was -$10.1M. FairStock's Lynch category is none because it lost money in each of the last four years. That is not a moat; it is a cash incinerator until reimbursement or partnerships prove otherwise. Financial health is poor: trailing free cash flow is -$7.8M against a $7.6M market cap, a FairStock FCF yield of -103.7%; the FairStock Piotroski F-Score is 2/9 and Altman Z-Score is -16.17. Debt is low, with D/E 0.07, but equity is being burned. Valuation: at the 2026-10-13 close of $5.04, FairStock calculations show P/B 1.20, P/E -0.80, ROE -152.04%, and ROCE -77.32%. The P/B looks modest only if book value is real and does not keep shrinking. The profit growth metric of 113.05% reflects smaller losses, not durable earnings. I see a speculative development-stage venture, not a bargain.

In plain English: ENDRA Life Sciences is a tiny healthcare company developing ultrasound technology to help diagnose fatty liver disease. The filed figures show no revenue and annual losses in each of the last four years, though one recent quarter showed a small profit. At $5.04 on 2026-10-13, the price looks speculative rather than cheap because there are no earnings and the company is burning cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K/A (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer